Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
NCT ID: NCT04479553
Last Updated: 2022-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30000 participants
OBSERVATIONAL
2020-08-17
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
NCT02239237
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
NCT01764204
A Multicenter Observational Study on Safety of the Herbal Medicines at Inpatient Setting
NCT04269486
Post-marketing Safety and Efficacy Surveillance of Motherwort Injection
NCT06636422
Clinical Evidence Based and TCM Phenotype Group Study of Zhilong Huoxue Tongyu Capsule in the Treatment of Stable Angina Pectoris of Coronary Heart Disease (Qi Deficiency and Blood Stasis Syndrome)
NCT06709638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Qizhi Tongluo Capsules
Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
Qizhi Tongluo Capsules
Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qizhi Tongluo Capsules
Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanxi Zhendong Pharmacy Co., Ltd
INDUSTRY
Zhong Wang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhong Wang
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ningming County Hospital of Chinese Medicine
Changzuo, Guangxi, China
Fangchenggang City Hospital of Chinese Medicine
Fangchenggang, Guangxi, China
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, China
Shanglin County Hospital of Chinese Medicine
Nanning, Guangxi, China
Long'an County Hospital of Chinese Medicine
Nanning, Guangxi, China
Luohe Hospital of traditional Chinese Medicine
Luohe, Henan, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Second Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
The First Affiliated Hospital of Henan University of traditional Chinese Medicine
Zhengzhou, Henan, China
The Third Affiliated Hospital of Henan University of traditional Chinese Medicine
Zhengzhou, Henan, China
Affiliated Hospital of Yanbian University
Yanbian, Jilin, China
The Second Affiliated Hospital of Shandong University of Chinese Medicine
Jinan, Shandong, China
Affiliated Hospital of Changzhi Institute of traditional Chinese Medicine
Changzhi, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jie Liu
Role: primary
Haizhen Pan
Role: primary
Peng Wu
Role: primary
Guige Tan
Role: primary
Zhenming Lu
Role: primary
Wanqun Wang
Role: primary
Xingchen Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QZTL-V1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.